Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.65 |
| ▸ | NOS1 | P29475 | 11/20 | 0.65 |
| ▸ | NOS3 | P29474 | 8/20 | 0.65 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | CCR5 | P51681 | 1/20 | 0.57 |
| ▸ | CCR8 | P51685 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844608 | 0.84 | NOS2 (0.61) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL12585924 | 0.83 | NQO1 (0.46) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL91288 | 0.83 | NOS1 (0.47) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL18291870 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL21847247 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL24003779 | 0.82 | CYP1A2 (0.49) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL1061501 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL30240847 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL7674585 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL3307860 | 0.82 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331134-A | Catalyst component for olefin polymerization, catalyst for olefin polymerization and application of catalyst component | 中国石油天然气股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2020247679-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2019-08-27 | — | — | US | disclosed |
| EP-2694484-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-18 | — | — | EP | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-5385914-A | Cardiotonic carbostyril agents for treating heart ailments | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0355583-B1 | Cardiotonics | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5198448-A | Cardiovascular disorders | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0355583-A2 | Cardiotonics | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | NOS2 2491/4885NOS1 1869/4885NOS3 1924/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | NOS2 4195/4885NOS1 3695/4885NOS3 4232/4885 |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | NOS2 1286/4885NOS1 1435/4885NOS3 1377/4885 |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | NOS2 3993/4885NOS1 4140/4885NOS3 3404/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | NOS2 4521/4885NOS1 4235/4885NOS3 4327/4885 |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | LPAR3, LPAR2, LPAR1 | NOS2 4826/4885NOS1 4857/4885NOS3 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.